Accuray will showcase its CyberKnife® and TomoTherapy® Systems at CHINA-HOSPEQ 2013

Accuray will showcase its CyberKnife® and TomoTherapy® Systems at CHINA-HOSPEQ
                                     2013

PR Newswire

SUNNYVALE, Calif., Aug. 16, 2013

SUNNYVALE, Calif., Aug. 16, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq:
ARAY), announced today its participation in the 22^nd China International
Medical Instruments and Equipment Exhibition and Seminar (CHINA-HOSPEQ),
taking place from Friday, August 16 to Sunday, August 18, 2013.

For the first time, China's hospital procurement officials will be able to see
firsthand Accuray's CyberKnife and TomoTherapy Systems at CHINA-HOSPEQ 2013
(booth #G02). On display in the booth will be system models and demonstration
stations featuring various products and clinical illustrations. PLA General
Hospital and Peking Union Medical College Hospital in Beijing are leading the
charge with these new technologies, having already acquired the CyberKnife and
TomoTherapy Systems. PLA General Hospital is the first and only China hospital
with both systems. Cancer is one of the leading causes of mortality in China,
with almost two million cancer deaths nationwide during 2008. The CyberKnife
and TomoTherapy Systems give physicians in China the most innovative and
precise treatment solutions to help make the pain and suffering of cancer a
thing of the past, and provide new hope to more cancer patients.

"We are committed to strengthening our partnerships in China, with the
government and distributors, to offer more patients the opportunity to benefit
from our effective, personalized treatments," said Kelly Londy, executive vice
president and chief commercial officer at Accuray.

"Our factory in Chengdu produces the TomoTherapy System's linear accelerators
(linacs) for the global market. Accuray continues to invest in this factory
with new machinery, and is continuing to further our commitment to quality,
evidenced by the factory's ISO 9001 accreditation," said Roger Cao, M.D., Asia
Pacific president at Accuray.

The TomoTherapy System is the only radiation therapy system designed
specifically for image-guided, intensity-modulated radiation therapy. Its
on-board CT scanner enables daily pre-treatment imaging for increased accuracy
and the system's linear accelerator (linac) enables the continuous helical
delivery of radiation from 360 degrees around the patient, providing for
increased treatment precision. 

"Clinicians use daily CT imaging to guide treatment based on the size, shape
and location of tumors on the day of treatment, rather than treating based on
how the tumors looked a week or a month ago. This ensures radiation delivery
with the TomoTherapy System provides highly precise treatments," Dr. Cao
said.

Accuray's CyberKnife System is the most innovative radiation oncology solution
for treating and tracking moving targets with extreme precision and accuracy.
It is the world's first and only robotic radiosurgery system, capable of
delivering high-dose radiation therapy with sub-millimeter accuracy to any
tumor, even those considered inoperable. It safely treats tumors anywhere in
the body, including the lung and liver, two of the most prevalent cancers in
China, and has been used to treat hundreds of thousands of patients worldwide.
Treatment with the CyberKnife System is completely non-invasive and painless.
It requires no anesthesia, involves no incision or overnight hospital stays,
has minimal side effects, and allows patients to immediately resume their
usual activities.

About Accuray
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that
develops, manufactures and sells personalized, innovative treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The Company's leading-edge technologies deliver the full range
of radiation therapy and radiosurgery treatments. For more information, please
visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical
fact are forward-looking statements and are subject to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release relate, but are not limited,
to clinical applications, clinical results, patient outcomes, and the
Company's leadership position in radiation oncology innovation.
Forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially from expectations, including risks
detailed from time to time under the heading "Risk Factors" in the company's
report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Qs
filed on November 8, 2012, February 6, 2013, & May 9, 2013 and as updated
periodically by our other filings. Forward-looking statements speak only as of
the date the statements are made and are based on information available to the
Company at the time those statements are made and/or management's good faith
belief as of that time with respect to future events. The Company assumes no
obligation to update forward-looking statements to reflect actual performance
or results, changes in assumptions or changes in other factors affecting
forward-looking information, except to the extent required by applicable
securities laws. Accordingly, investors should not place undue reliance on
any forward-looking statements.

SOURCE Accuray Incorporated

Website: http://www.accuray.com
Contact: Rebecca Phillips, Public Relations Manager, Accuray, +1 (408)
716-4773, rphillips@accuray.com or Kaman Ng, Marketing Communications Manager,
Accuray Asia, (852) 2247 8688, kng@accuray.com
 
Press spacebar to pause and continue. Press esc to stop.